Roche Holdings AG (OTC:RHHBY) on Monday shared results from the phase 3 persevERA Breast Cancer study of giredestrant combined with palbociclib in advanced cancer patients.

Trial Misses Primary Goal

The trial included patients with oestrogen receptor-positive, human epidermal growth factor receptor 2-negative, locally advanced or metastatic breast cancer.

The study did not meet its primary objective of a statistically significant improvement in progression-free survival versus letrozole plus palbociclib.

The study showed a numerical improvement.

The adverse events for the giredestrant combination were manageable and consistent with the known safety profiles of each treatment.

Roche Sees Path Forward

"We believe there is a path forward for combining giredestrant with a CDK4/6 inhibitor in the adjuvant setting, and we are conducting further studies. The efficacy demonstrated in evERA and lidERA provides clear validation ...